Pfizer Stock News

Buying quality stocks when they're unpopular can be very rewarding.

I went to a Prince concert years ago. He opened with one of his hit songs from the '80s -- Let's Go Crazy.

PFE's sell-off triggers a rich dividend yield of 6.73% and double digits capital appreciation prospects, thanks to management's focus to "enhancing long-term shareholder value." Despite the patent cliff headwinds and IRA Medicare Part D redesign impacts, its core portfolios and strategic acquisitions demonstrate robust growth profile, particularly in oncology. These developments underscore why ...

There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're looking for a way to raise the stream of passive income your portfolio produces or you simply want to outperform benchmark averages, adding some dividend-paying stocks to your portfolio is a smart way forward.

Looking for a good area in which to invest? Consider the healthcare sector.

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annualized dividend income. I added to positions in Pfizer, Starwood Property Trust, and Reaves Utility Income Trust, focusing on undervalued stocks with strong dividend yields.

You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers?